Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Diflorasone Diacetate Ointment 0.05%. This is Teligent’s fifth approval for 2018, and its twenty-fourth approval from its internally-developed pipeline of topical generic pharmaceutical … Continued
The post Teligent Announces FDA Approval of Diflorasone Diacetate Ointment 0.05% appeared first on Investing News Network.
Original Article: Teligent Announces FDA Approval of Diflorasone Diacetate Ointment 0.05%